Long-term safety assessment in children who received hydrolyzed protein formulas with Lactobacillus rhamnosus GG: a 5-year follow-up
Open Access
- 15 December 2016
- journal article
- research article
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 176 (2) , 217-224
Abstract
Extensively hydrolyzed (EH) formula with Lactobacillus rhamnosus GG (LGG) was demonstrated to alleviate cow’s milk allergy (CMA) symptoms and promote faster acquisition of tolerance to cow’s milk protein. We previously demonstrated that partially hydrolyzed (PH) and EH formulas with LGG supported normal growth in healthy-term infants through 120 days of age. The objective of the current study was to evaluate growth, development, and specific adverse events through 5 years of age in participants from that cohort who continued receiving study formula. Infants who completed a double-blind, randomized growth and tolerance study were eligible to continue receiving the assigned study formula through 1 year of age (control: EH casein formula, EHF, or one of two investigational formulas: EH casein formula with LGG (EHF-LGG) or a PH formula with LGG (PHF-LGG)) and participate in follow-up through 5 years of age. Anthropometric measures, behavior development, and specific adverse events were recorded. No significant differences in achieved weight and height or behavioral development outcomes at 3 or 5 years of age were observed among study groups. Few statistically significant differences in the incidence of specific infection-related events through years 3 or 5 were observed among study groups, none of which were considered clinically relevant. Conclusion: Extensively and partially hydrolyzed formulas with LGG were associated with normal growth and development and long-term safety through 5 years of age. What is Known: • Infants with cow’s milk allergy often experience allergic manifestations that can lead to poor nutrition status and poor growth. • Providing partially hydrolyzed (PH) and EH formulas with or without LGG in infants can support normal growth in healthy-term infants. What is New: • This study provides long-term safety data for the first 5 years of life on the use of extensively and partially hydrolyzed formulas with LGG when fed through 1 year of age. • Extensively and partially hydrolyzed formulas with LGG are associated with normal growth, development, and long-term safety through 5 years of age.Keywords
Funding Information
- Mead Johnson Nutrition
This publication has 53 references indexed in Scilit:
- Probiotics for the Prevention of Antibiotic‐Associated Diarrhea in ChildrenJournal of Pediatric Gastroenterology and Nutrition, 2016
- Probiotic Lactobacillus rhamnosus GG therapy and microbiological programming in infantile colic: a randomized, controlled trialPediatric Research, 2015
- The Use of Probiotics in Pediatric Gastroenterology: A Review of the Literature and Recommendations by Latin-American ExpertsPediatric Drugs, 2015
- The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probioticNature Reviews Gastroenterology & Hepatology, 2014
- Lactobacillus rhamnosus GG: An Updated Strategy to Use Microbial Products to Promote Health2012
- Functional Analysis of Lactobacillus rhamnosus GG Pili in Relation to Adhesion and Immunomodulatory Interactions with Intestinal Epithelial CellsApplied and Environmental Microbiology, 2012
- Dietary treatment of cows' milk protein allergy in childhood: a commentary by the Committee on Nutrition of the French Society of PaediatricsBritish Journal of Nutrition, 2011
- Safety ofLactobacillusGG Probiotic in Infants with Very Low Birth Weight: Twelve Years of ExperienceClinical Infectious Diseases, 2010
- Evaluation of diet and growth in children with and without atopic eczema: follow-up study from birth to 4 yearsBritish Journal of Nutrition, 2005
- The Efficacy and Safety of ProbioticLactobacillus rhamnosusGG on Prolonged, Noninfectious Diarrhea in HIV Patients on Antiretroviral Therapy: A Randomized, Placebo-Controlled, Crossover StudyHIV Research & Clinical Practice, 2004